Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Feb
14
Today In Oncology
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
Oncolytic Virus Triggers Immune System Against Glioblastoma Cells
Adjuvant Durvalumab in Resected Early-Stage NSCLC
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
Young-Onset Pancreatic Cancer Can Alcohol Consumption Raise Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo